Lubris LLC

Rhode Island Hospital

The Schepens Eye Research Institute, Inc.

Edward R Truitt

Benjamin D Sullivan

Gregory D Jay

David A Sullivan

Tannin A Schmidt

Jawed Fareed

Joanna Szmydynger-Chodobska

Khaled Elsaid

Roman Krawetz

Adam Chodobski

Nicole Barbara Justis Truitt

Tannin Schmidt

Nicole Barbara Truitt

Tannin Avery Schmidt

Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-&#x3ba;B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Use of PRG4 as an anti-inflammatory agent

Disclosed are methods involving the therapeutic use of human PRG4 (lubricin) protein, to improve vision, to reduce aberrations such as impaired night vision, halos, and glare, to improve the stability of the tear film, and to homogenize the refractive index of the surface of the eye.

Use of PRG4 to improve dynamic visual acuity and higher order aberrations

The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Application and uses of PRG4 and therapeutic modulation thereof

Growing community of inventors

Medina, WA, United States of America

Edward R Truitt